Key result
Tricyclic antidepressants cause conduction defects and arrhythmias in <5% of patients, whereas newer agents show lower cardiotoxicity.
Why the study?
The frequency, severity, and clinical importance of the cardiovascular effects of the various types of antidepressant drugs in clinical use needed to be reviewed and placed in perspective.
What are the cardiovascular safety profiles of different classes of antidepressants?
What are the cardiovascular safety profiles of different classes of antidepressants?
Answers are grounded in this paper and cite their sources.
Classical tricyclic antidepressants carry significant cardiovascular risks, including postural hypotension and lethal arrhythmias in overdose.
This monograph comprises a review of the cardiovascular effects of the various types of antidepressant drugs in clinical use. The frequency, severity and clinical importance of these effects are placed in perspective. Most antidepressants can cause changes in blood pressure. Both the tricyclic type (TCA) and the monoamine oxidase inhibitors (MAOIs) can produce postural hypotension which may be dose-limiting. In addition, the MAOIs may be associated with severe hypertension when amine-containing foods or medicines are ingested. It is unlikely that therapeutic doses of any available antidepressant drug could impair cardiac contractility. Typical TCAs can cause abnormalities of cardiac conduction and arrhythmias, but this affects less than 5% of patients, mostly to a clinically insignificant extent. Newer compounds such as lofepramine, mianserin, trazodone and viloxazine seem safer in this respect. Reports of an association between therapeutic use of TCAs and sudden death are far from convincing. Overdosage with the MAOIs, lithium and carbamazepine is dangerous but not common; overdose with a TCA is a major source of morbidity and mortality. Lofepramine, mianserin and trazodone are relatively safe in overdose. The use of various antidepressants in patients with hypertension, cardiac failure, angina pectoris, myocardial infarction, or cardiac arrhythmias is discussed and guidelines suggested for the selection and use of antidepressant medication.
No takes yet. Share an insight, caveat, or question.
SJ Warrington (1989) conducted a review in Cardiovascular conditions (hypertension, cardiac failure, angina pectoris, myocardial infarction, cardiac arrhythmias) in patients using antidepressants. Antidepressants (tricyclic antidepressants, MAOIs, lofepramine, mianserin, trazodone, viloxazine, lithium, carbamazepine) was evaluated on Cardiovascular effects (blood pressure changes, cardiac conduction abnormalities, arrhythmias, contractility, and overdose mortality). Typical tricyclic antidepressants cause cardiac conduction abnormalities and arrhythmias in <5% of patients, while newer agents like lofepramine, mianserin, and trazodone are safer.
Synapse has enriched 10 related papers. Consider them for comparative context: